HUE032072T2 - Új kozmetikai és/vagy gyógyászati kompozíció és ennek alkalmazása - Google Patents

Új kozmetikai és/vagy gyógyászati kompozíció és ennek alkalmazása Download PDF

Info

Publication number
HUE032072T2
HUE032072T2 HUE12186394A HUE12186394A HUE032072T2 HU E032072 T2 HUE032072 T2 HU E032072T2 HU E12186394 A HUE12186394 A HU E12186394A HU E12186394 A HUE12186394 A HU E12186394A HU E032072 T2 HUE032072 T2 HU E032072T2
Authority
HU
Hungary
Prior art keywords
abi abi
abi
skin
oos
composition composition
Prior art date
Application number
HUE12186394A
Other languages
English (en)
Inventor
Andre Ulmann
Jean-Frederic Sturer
Original Assignee
Legacy Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legacy Healthcare Ltd filed Critical Legacy Healthcare Ltd
Publication of HUE032072T2 publication Critical patent/HUE032072T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Description

mMmPwM: ffsf Ibtete (Piflídrfiip?: .dü of tilso obtepasite iteiödfóbste ante tesb §f$i$$bf|,:as·: saspó|>t&:
Igomg tete; sited tesi m$ teán esscs rpvs
bean <fe*es$feeö to tea Meretom Tbese oomposiii&amp;ns css bo ssed especially te txmmm fó:te§utape tea ispxrwte oí narr or )Γ; mr^seaUcas todtoattorvs te promofe ontogenesis, siteiafe fee syr«h*Sí$ öf ctipl mé termelted teremlifemters s?te schvtemn of ??íasícells. and tersed m tea beaten* of estei concern Amoco tea Iteefuse mte-neo-s tess may sx· ttod, fór **a«ípfe. sre tbs Fiasco pteení applletefóns No. 2 875 403.. 2 877 210.. 2:672 224 2 Bf? οή aoo 2 8# f 4öO sf Ifó Swiss palent appilostetere &amp;32 217 A
Tha applicant te etesj saw tompkor·,* tecn m tetess tes ess m cosmex's or temen teeraey te '.véreb tes· sípiitewfland bigb sfabíiy os ide conrpn&amp;dloms cfesanfcsö in m mmp> lea abjeoi of tea rnyentsön is toes se* eon:pos!soos cbmacrerfóers by m fecl fea» ttey se estei el Crime steme esd -mmmm.ml.Qipmmiz.mcm Site an exbaeíof Th&amp;o&amp;m* ψ$Ψ$
Among fesse tease widen are of more psterlar rterasi are <»TipöxfecnS as seized above, teaefteete tbaf teey tef«ia an ^eous-afóoheiic extrást dfA&amp;m species* pa aqpAoqsteöPte a^texb* φ'..\%% «*-4 -fro so sqrte teocx ,· te ..: -.tete 0' r m -a %mtea teems ana an emete>χ%-- mte" (átenged ot eoti of TAecémms sptec •oísíi spireses sxüacl (gtomjsfed rmnod sí ardra speers* and 28^ ««ιρ^δκ?.
Among the composites according te tea marten tease winch see of most psrSotear interest are composite as defined at»*. teeming ter 65% te 65% of an eqm-oas-aiontec exiract $Mim #ateaa. from 5% to 33% of an anew ateoite axbaef of ters cpectes. fnm 0 26% te 2.5% or an oq.mous~arooboiio«s!raof mteiaed or nor) of Poacey teld fte iöisf: fó 2.55: oi an aqteerr-ateoiic e^aof faromised or asbtef mptmva opeoes sard es?5eaa«y teoas sateilrtefi ftefteH to §3% of m sqrrtes-afóotec Sitef of A&amp;aar oepa ter 5% to 33% of an ateoavSteoteo estei ^ W „ X V !K !"> ' " ' ill O^OteSv ^fó«"S<r'.' ^ A <
to 2.5% ¢1 so squtes^alteitee astracf (aiomrsate er oof) o? iftooite»e spaoiOA 7m· term extef o? AStom qpsetes &amp; aqeeous-aitecic e»tet of Aterr «peelea ré^r^rSourá^; to exrraote and teve extefs oblatead froro as spec*» or tee seonc Aföito* if-Ady IM&amp;m) ana eopaoi* Aism espa. gxrrscf of Otero texte cr equeobs-ai^c e^ct % Coo.x apec^ refers ^Jcutody to ^ rrafiva exiraefs obtomed frorr ari species of ere fenaa Crte (fer^ly Ateteoete?) end e&amp;peofórry Ormterte
Fxrrpd (atomised or rroq te Fdrtera speem or aqrreoo^arcononc etecr fefomised or nor) of PmSMa speem refers parteiady to aqq«qSteoilc exiraefs te nairva asoaers opiate m ® of tee germs tete; ftentey
Saptedaoaaa) and sspsciarry F^otea ooeane.
StecUatomite or not) of 00¾ Φ w-·
Parri&amp;dady ro aqaaous-afoofiaiic edreers and naiive exiractSfobrained te aü soec-H of tee genes Mfófóa pbiy hjalvmm) and sxptesiiy Ttetetea cacao *» cmotmmw****10 **» **» *** m m tmmmsrn: +** *» coding from ®* » <* * «*" W&amp;V** *» te ^ of on mm»**m extract of ^ *»" ass% 2·^ öf ^ «»"» «*** (*"«** * Sm fí0«: D.l%io 1% Ofxmc m'® *i#*»*««^*“ oi Ammi cej». forc, 5% » 33% Of 00 *qu*öute*te* Q^ M kötn °'25% ^ 2 5% 0130 *^^ααΜύ <* .«0 of Sm sot and from 01% to *% *« ·**· ^yom>
Emu oi Sato *·** « ·ρΜ» ^sct «MM* or not) s>f Sato ipasfce rate fo οο,βοοο «Μ» wed Ü® m amm of the genes Sato «Μ» «**·** **““* $*s* «ft»
The ,;;-,c $iíspiKítö USitd .n jof nso^ioiJS «ecom-ng to the inventor- may 0¾ io m iom of bn anhydrous saR or 3 potyhyöreied .safeíOSpsOíelly f f^is: T os mosi preferred compositions -acoos'Ofng to ih* istventas am. ?noss eontainmg 87% of an sdneons-sleohoilc extract of Ai?®m cops sprstoximoteiy 12% of a, oaueous-^ic extract of Dime ten* epproximotety 0.¾% of on *ψη<»*α** fr»«x {msed or oof) of te*#, aw 3ni:sppref«máí#í|J% of so sqiafout^^we*^ mam or non of Th&amp;Mcm uc#>. as wsii so boss containing approximately 8?% of an squeous-aioohol-c axfrert of Atönm cope. septoximafery 18% of so not) oi Ssüx sioa and 0 2% me sofpnsfe haifapydfPte,
Ano8iSf object of ms invention is s: mefesd .Ériihsi^si^f'Pf^i^ö^ Sigh tp;||gse:;^ pmpmstbo of » castor «ttttm cr^^iÉs:o##m#£WMI*«fe* #0l %mx ^ m sxtmotoi Paoifisb spécim? end so «Μ: : án ^.^ííto#f: $e;-iteo, io give the Facetted eomgssbsn.
According fo bo pmioresd conddions fert^gjWte^ b mat bo mate solute is prepared oy pjtfing. crossing end sailing be several hours in arnettsl and filtering, men mlpingite^
Id eing mis method of preparation for me cornpoxmoos sccordmg to free application, a reeoinnsended procedure is fo prepay bp master sobdon tom be oonsflrsdis. by piling, crespinp and miidp be áÉmrand the Dims, rnr^ng wmr 9o5 sfcohrs macerate m the cold to? 48 Cooro, fstonng be nnasbf sn'-mcn througs 0 22-mlcron biors to give &amp; waferosiconoi syrrnr.i ^ifh a io^y confenf of panvoios era men anjrrsfirrg ms s^rrscr cnov^ed ry -r.; acn::0: Iras nrastpr soiption 4$ tirpP:. tmafed, by s-mpie mixing, eibor wftb me^tfpas iafombed <>r not) oi Pm^nk spsebo and njoobromai|^% grryfi bp sxifsd {afornssed or not) of $&amp;8x species Pius bb ϊΐοο solpbaio
Compostboos suof= ss boss dosco&amp;M abw$ státifc^ fnmrpsiiijg proposes «fsicb msKs ten seiisols dvrtrxp in sasmete.; in co%rooifC appiscaboos. those corr^posbons may bo used ® miKukv for asfitroing ante sfab|iin| % osndi«dffs pfiectiag the skin, the scalp or other externa! pans of me pody, and especially for lowing down the loss of hair; slmplstln| ik cowth iecfeasmg do density, eiim-nating dandrnf? ofrssftsrg rbe srgos of agemg of te scalp and msahfig srry dlsmrders of the η,ΐ«§. ror top-cat oppf!oabon. those oompo^eonsanay thoo he apprmd drreeny to %», sbn or the scalp eppiroatinns daffy m me fe!w of selotions gr egoeentrsmd mfrons. for essrítpre. wüi? a conc^íiirsfismaf &amp; 8Ö%:. txdfbolily epprorrmamiy 20%
For ftoerneric. cpp!iCOiions; the cofopeshions may also tie ödírísnisfered as food seppmmer-rs -n the form o? grannies, sosifne oapnfes or dneks, doyrondmg on ms brat form reqwrec srd sncfead of o&amp;rg the pfrxioef ·η fee loon of so aqnooas ak'obof-c 8ofeüöí».t^Mt*8«f!·:*δ ^ pro*#* - « *y te* <&amp;&amp;**} fa** *« wk**5**· ** zj ********** §'f?*ae- divs?5^. vv:KS:^;8;;v;· OS' SSSCOiXiSfy exp'gettoe d? the ΟροδΟΟδ-ΟΐΡΟηΟγ:·; Solution Vil=h Sispef-omsCa: !.,cí.. CVoposIK-os eucb as those deseoped $xm also show properties TO^v raay therefore to sdmlfvstersd to tomans or amoiats as fstediiim especial as therapeutic or pihy!*át niedronee
so py&amp;atar, these composái*» way be use* fc? fcestiög deabaiesls. "m paftkoiarty <tefmam:s doe % fmm cutaneous p&amp;eteriat and v03i iofectrons. ageing of the skin. bleaching sod -.sPstcniog Q> &amp;s skin. vrio-go. acrodetitsahes, aunt-irsd-K-ed fsetimci easing of toe sk=o sod yanous ecnd-rlons related to eunfbys {phoiodurn'siasis). &amp;t-o os any origin !ís%íOíoeto?y c-r papule pustule), sene rosacea, topos ef^hemetosus. sensitive #nn.. mseit svngo, e<ly of oty stun. sSoouhe*. Udders alopecia of any o«§*.. hair toss, pjtydavs cajs.b$. p$m. sensitiva scarp. ytm? aatr. psohasrs and parapMi»»» of toe scalp, dyshidrosis. wests suid coon, scarsas angular cnaihs and oedsros, or soy orseases capable of .aaocu::g the OSilS cfs tneraey. Épe íCompdsitÉos also hasa as étidet on caernYascbiahsaben ss5d so iftp tip ssitlotipo of wouods, stiaohonsofaoy ori^rn bums. fetotchias§&amp; Bsfsgafs disessa; cutaneous porphyria. aR§*msiaá ma^na* mmmMi They may also be used m iherspy for trsuttnp disorders of korstinisatrory as wed as kerataSc fusions, hypeikmatoses ff®#ig karafodorirsa! dyskeratosis, larfrrs dissass. porakerafesls, kátiÉyo#!: «»9ί:::;§^f©isiiB^»i. i>chso:i;cati«o scaly domiatosis;. prungo. chersids and pustulosis. F^sy ««y rosy be used itrfs<s% fiaamorreoidal pressars. ih;s>ebofio s%ctioos: syrnpiufns associated wits veno-iyiYrpnasc iosutrrcrerrcy. heavy saps mi paresthesia:
The cornpositibgl fóipJi f.el seat or: 1¾ ^íÉtW':'-t^c:8R#"^as^s*f:'U»: ooü^oassdS:: st; aus »* : phaorsaveubeat compositions cesífaldiop ea etfeuíM #ü Sa fa® acavo taps^ddt;. stfetber veth sfanaa;o: pngm»*atjví?*.jf:: : tne*t exolpesds aodfor aOítlhvdsi
Tease pppfmaceutlsaí Wt :-M sf: paraaferftl touses, py iocal ípoieaí r^>p’lcaflO:f íö m m>- aad tae ma&amp;m. or by áeeetlorp fcr escasople py sats^tafsopus sajeespd. Tíío p-foasctaes maycgtsd p§ p^f exiopfsih §:ΙβϋΙ% cpstéd^ Msfets< capsules, soft oapsefosv ssfüifpds. ffei^adipjl#^···^^· lorrp faqu<rod. it wstPe Ρ«8|ΐ^..ϋ#^$;.:^ι^^·^:·8ίδ·':!Μ8'?ί:ΐ?.
AdirunlsPaboo Is also eossmle by ma oxdat műié. fer exam^e. i» the form of sopposltoaas or by tbe parmvtaisf ?ουΐο( for: exaropte la the fórra 0? cqocraPre scsuboas or iafeslor'S «fcrocapsules or ubpraots, py tog pesxxjtsfiaeus roots: for essmpsip to the tboY; of ^ byotief rpuras euop aíí: those: iasolvirsg: aerosols or nasal sprays. I'Pese pttófroaceutíca? oempossbons are pfepars-d by eerweesoaet rxatfíods· ;n vehict: pharmacaetsoany ciast. oí§«ok or lnof|anic excipients arc added to
These pemposnions way Pigiefore be soirds of liquids, presented In any of ihe phsrmsceuheat toffps mm8$j «sod id Ρυργορ p:öd:C:ne. m fen- example pram o>' sugsr-oeaiixi tahrefs. 05¾. bxenaes. capsules, orpps. grapuses. rpjedfSfers: prepafaisons. omlmenp. sreant$ os' gebe topárad by stsndafd rrseU-ods iffpr ise prsdrreioo ot arain or suoer-costod flbtetp; ppsfep ifefjsefs: add daro .psiapneisapspias: if is itesspa fc o»es ibr exampfe. lactose; corn starch or o;..::abts; car-sera fw sett Qersiine e-apsides οι k-i supposlurrfras ooffipfrse fóf ex'drepse, rats. vrSxeSi serrfs-saiid or eouro ps>pO:S. naruríé or rrsoísstied o>h esc. SultaPte vebsersis for sna preparation of ^otubiomi. tor orers'-c-se. csyKia^e sorutfens, ssrnsdssons ur 3 vs ups. comprise. for example, wafer. afeodols, geoerof polyols, sucrose, -nyeri soppy gsooosa. vegetable ofs, sic. popre carrier* fer mjesooepsures or =mpfenis cernp-íse, fos sxampse. co;X>iymers of glyoxaiio adsl and sac Do add Thu supuu feqsespsp as defmed above may be blended with ide exoiments oss;aüv employed is- pnarmacerfeeas epmgesttea, pob p ppm^pmipsife! ls#ss,::;sfareii rnppglm glppfe oopa ppfe:|ppg|;:p^ vsíhsues. fetfy spsfenees of ananas or veg&amp;tebs* oögsn, paraffin derivatives. $ycofe. vstknjs #ettm§ agents, dispeople w aTiolssPrs and preservatives. fe> M^p%.|E'8@Bwhgmdfén^|:|® #|s^|:^í3v«:p<f'Ét síxöÍ |»H@ííT! sesü f s ?^sy epildíabdlyes: sasi; as( öiiuents. dismipraferS: Pnders, iyfeneams; wsdlpg sosnte, siaoiNssp amoisisgís, pfbs^rvas^s, evaxÉmeffe edorsms; fíavocsrs or fragrances. fPteners and buffering agsnfs. pb also sivgpiís or solubilisers, refördap OSPÍOSO: prossoro^o^fyibl ®r sniWbpis, 11ís: feveilbn also inotedss ghsoBssosüoss cemposPss ssofaio:?ig: sfiiteasf m&amp;M··ifc drog* Ütesd áseve .as-ssÉvs: io|fidf8«f.í
When mpg sós compositions obialssed according tó ebe invention, dosp may #?y within relatively wiP limits and must he M aeMPi feie pornos? Peng Deafed and fee suondlüosx dzsemed, Pharmaceutical compesfeie normally oemsín irosn 0.2 to 500 mg. Isom 1 fo 200 mg, of aehve ^gradients as defined simvs. m me torn* of dry esfeam For mai 0.06 and id mg&amp;g, preferably from 0.1 to δ mg/Ks. partotady from 0.1 to =#.|©-§0^=mg as appropstafcr an adott :%pÉ|§jiendÖ§:pf#$^:##lfaffes approximately from 0,0¾ fa 6 mg/kg. preferably from 0 f to 5 mg&amp;g The daily dose fedf life divided, especially when | large gmhp! of active ingredient is If |e aProwfetered .:S^ííiFis^:^'K^^|^iÉife0ríííi^liiieirQV^-ba- given hdlöt^ so as Jd Htissytviyt^ tHd of th« frsy^fidorv in a nommsfectlve matter in vsew' of fee mature of ins products, a hearaaae nr eebume shomd obviously 0s adasd when they are fo be ased m ifeutn or sobs fesm. EXAtUPtEg:; ppmgie h A composition was prepared comammg; ·· m ppoes· stsxfeotio extrást of Ahm « Ifit* %: · m agdsoas'afpoopife mdraet of (¾¾ ΐ&amp;ηο»?" t1 ·% % - m afon-isad aoasoys-^conoiic eaftscf of P»s0n$mmmi 0 £0 d. ·· an ssornisad aqsaoos-aicohoiio extract oi nwoProma sacao: 0 £g % ' \ \n >v x ve ^ c!«;> f v i O' \ ap eno Πη«ι(Η; w ' ' t-' "V1 Pt 0
in %' aicotas fo; 48 doers is* me coin, iledng thfouyh a 0.22‘micncm ». oofienhng fire ásan|felife5fe and ardssfing fo 3(^ aiaohoL TAe agaeodO'afeohoifo aafracf of fernso was psaparsd oy p^^ind. crfes^issa arrd reiifing the OfOia. inacsxesrrg sn ffes afgsfex fer di: hegre ;r: dw cafa, fSienog feroegh « Odd-fiewee oner, oofeeng the asaonoiü: firnafs ano sd^siing fo 3Ce aioonoi. :A master sbidfion r^ ektraeferof Mám simple m«§,;::me« ^asoas*afeeissiig etdracfs of Pauferisa coAssa and rtwoere^a cessa wsreaddssd^^tellfe master.smsrnmaeigwe fho nsgyfrad combi-md expasr.
Oxamoiti. A oomposihos· was propasad aonfaísuiig: • an aqoepas-aloGhoffc axfrscf of Ai%?rr cepe: ST 30 % ao extras o? Csryst&amp;ti&amp;fg: *<ρ·&amp; >.' ·: Sf5 3|öí?íÍS3íj: gii|iJíKíí:ÍSf ^8$$ Μ ^Χί^ίί A ^ , síbe sulphate höKShvöíöís:; {i ** '>Λ
Th« aqueoua^fcohois e« of *®*s c»p&amp; v*a$ iK&amp;eared fey #3smq.as$ rrtfírftg tN macaraling m 8* áscohd töt 4« bmu ki M $M> ^ou§h * 022-m*c?w Mm. «ofrtfwe m a#s&amp;«8 K> 3iA alcohol Ís::ap^®*ihh süsd MM** kmr, was pmm$ by ^n$. s&amp;3ft>R9 3¾} -«MceraMe is 3^' alsötófcr df ΡομοτΙο lbs sold, Sifting through a Ö?2-ralcron te. coifecstag íh* «conolfc:Íi|iuj and adjus^O ío 30s alcohol. Á mm® mMm mMtm 8* Φνψψψ, ápguos : eximc? öí Sete síbe sód fbe zinc sylpbofe hsxaiíydralo wsroaoded >0 Éis mester solarise give the r eqd ;md: édÉideddÉfSOt^
Iiisiii A fosa Süppíomosd was· iparod Ρθ^Υ4||: * a dry extract <sf Mm ö ''04 * - a dry exirasfof ($w$ f&amp;w ! -!ti ^ > a d?y sxfract of Ρ®Φ$$ wperm. ^ * ^á:d?Y oxtraef pf 33!#o&amp;íomo escao $%$"&amp; -fals was obtained by adding so aroma to the compost obiaiasd * Example I loo thro tha m<xn*> ίο gf*s a powder whipfrdqb^ s food sqppiimsnt ÍMSiiMí A mmte mtico «or scarp Irsstmesd was prepared irons *he feiioviepds^^^·::. · composttiOd obisieod <n txaswgte 1 -’ '* ífxoipier|:qópíÍ«ió|Af pqddmiigrdibbl ·ο§«α
The bis* wee prepare by simple mbinp t* id* cc*pca$*i MM In Exacts 1 and an axopianl ixiil&amp;i A cmdicinsi infers ter aoaip uesfeerc wax prepared from the fefevwog onmnonesfe .*. -.v 4fv?t^ - composrim obtained «a example * :, sxcipnmrqsp bodubiog pednsoe/arosrsa) i!
The infers was prooarfe by ssmple sniXsog of me ecxfeositjon oofameo so r:,xa?Rp* «ad 3n ;*, fesm>
ExESli; vyyfh the hylfowf 5¾ íidín'ífifgjlf 00 pcfe fXfpstbbi , composition obfeusd in £,*«mpte 3 ϊ5^ • exdpiooí qs.p fsoolí-icjlog pertliíae/aroeiöl -v”? ^ (•>scid«nf delaid: iaotose. teioum. afirsbí ai ^dOSíMíd stoarato.· liiiliil:
As ddpReelür^^medldiciosa wasprigarax aa mi 'bomgosiiion obtsined in Exampiaíl 55 ϊ><: - axdpie-n qsp (iaoludinq parfdmaAafomal 5 — '
JlJi» mm *m »55 »«*»« «ft» k> <***m Μ» l«« «- «of» mm mb mmtrnmm^mmmbm0mmb < (»< w* W* '· *W* <**** «*** <W* * mm morn * ft, mm »5 «**« of ft· **#«**·* *» iff «*8 c( la mmt «5 ·* WW ®* }:: \y)y IV: ,iSi0ii£S3SiC5,t '.: ' :: ;;:£ ,,:,¾ ,,, V íiJSriSíi I- :’ 11¾ sx5t?x:0; was sis following· D* t: to»S«, <>S ft, l«R*»l «. mmmvm <«»
Dap 1-2' no application of produso as sharoppoUfl: D«> ' , ΤΛ Of»' , X ^ w- =1 (W ,!" ' 'Vi?'
Cap 3*42; application of tee pmp«ette the %&amp;&amp;&amp;&amp;&amp;&amp;**
Day 42: ovpteeooo of cap»Dsy sap $Dn teteiapote Deacon of toe temporal site, sfoss οοαιοηΙορ ot if® o&amp;r a? ihe ppsat $f éteargénse-tom #5« scalp, macrophctography of the region siodtea Days 42 · 43' ns appücsiton of product ana no eharnpoeino,:
Day 44' fresh toacropnotepraphy of if® sams tegmw &amp;<&amp;/ *>
Dap 44 - §4 apples of the product «dm* to a® scalp f^o a day (20 <* «** occwm*. to Do ^ :>f sross-sectteri of too hair at IPs point of emeoasnoa from tee scate, i Day &amp;4: evaluation of osspitlafy and stew ioferai'oe: Deacon of the Ipfoporal site et tee rdf I* stedteíi ρ&amp;«^»8ρι®ο$§ Of ffte Pair at tee ppte? of emergence ftom tee scalp. otetexplxlostephy of tee iogsoa stediete Days 84-85 no appiioarion of IPs pexte and no shampo;>og.
Day 86: new inaersphotssgraphy: of ifitesarnte sápién ss afiSiayxr apa study showed:
> a aigteteotpf woplf: of ffitetefsnf:; etshstisaily ^fÉ^t;É#fh#e # Ife AfT : teiOif'anspaoldfteipipoteSiOtil of i*4Ap|> ^significant aatl-haiiloss effectiveness after 12 weete; of tfpoto'ont: statistically Significant i no ease in the AO ratio rasa t .. v s- - te, >·\< o qs. \ u a' " ' v ,x Nn a 5¾ hv. < 0" o' ^ *\ \ 3 aa x -i gpid sofaepfivoteiloivaf foteraisce: tetef htee? %p product of thoapvssnffOP: woo tasted on ΑοιίΡΚΙplates: Using woDxnown teats, tie d&amp;ve%ioen? of ondeihefiai ce?jS ^ : ^otefuro with fterobissfs was chocked., ono too fonoaiion of cepillary sfted&amp;res ftuhutes} was ebsafveo : no P'oocrf tested Í.i^^'^n^t^^:wesd#€Í^í^fc<«atÉi#k.bte:^rf^nst^v:,iorfsin wells adoifioneiiy socteved an aasyater tVSGF) while otrsx walls rscoweo a« inhtelsr fUi8asxfpe},®oase: wefts Toe noteent medium wss ohaaped at dsys 3,4, ?. to ^dill-and^e^'^'to^8^ aidsy i§,
Tfte sesufD observed on day 15 showed tee* ?n* orcduci has proncunood angeogenic activity

Claims (1)

  1. ÖÜ K00M£fiS£At |ÜVÜf GYÓGYÁSZAT* KÖMKfZiCiQ £$ £NNEH'Mf%&amp;§ÁIÁGÁ: igénypontok t ¥m®zm< »*!y &amp;tiv afkotárosíMmt *%«> tamMft Wtmm, am% Alkum falta (spooky M&amp;M8ÚW, m ;€És58 falta «xtrakfumsfedk t§y Pajfeís ipa axtrakturnaböt és egy tpaobroma pfs sxtra&amp;fomlb&amp;il aikima^m a kövsíkazo betegsége* és febdoltenosspek Kesére: bdrtantetem [defteatestsj, a sebbegessdés. <**««Β«ή rendeltewsssegel s szarosodé* (fcsfatinoation) «ende^esség* tmmsámi károsodások {ks?s*QSo festőn) ás ksungés* fcímtffatéry) vagy és mozgató jvasoimotor) rsfidPaoéssbgéb : 4-' ", . 'SXV'~, anob a»K ο^οόΒΛΟ xp ,m Sávoly toxamaz amp p·, A^.m S to ymvm v vrzas-P*oPokfs erff3>*#n*»6i. agy Citea; 1φ» vizayalobok-a exáakfyntábot. agy Psttloí* fajta vi*es-#öbok>s exíraMomabOk amp ímrlasztDíf (alonvsgöivsgyoapvporiaszxp és egy Tbesfmsa fajta vs&amp;ss· alkoholos sxbax'vmsbp bmp pcfapfp vagy ríám-plalöot, 11 3 A?, t. ípny0->ni szímatl kompoxieé, soot a börbánralom (Parmaxsls} a következők késők választható ki: borbsn!«om: smaly a követkssd okoknak tuiajéooltható: a bőr |^t^s.:éii#ttm->Mzés4 *;£&amp; 'ÁtegsáÉsp (sg«iog}: a bőr {bribing; és Kdehétedése pptpog), bőr pigmsntbtany (Pskgo), νρρ§1 Prgyatsabés iacrPanosSttrsb a b$r lény áltat indusait öregedés* taolsic ροϋΐ), továbbá kúloaboP kórülméoyek. amsipk riapsogarakksi kaírcsolatosak ipnotetfet (itatta·*). b.smmoo eoxretö so^ooé? pam [közönséges Poppy gyavadás^ gofenmaiory· vagy IPsem p-piPPs tp-mm.c pns»$ar}[ rozaoess paftanes yvme mssooa;. tapos srytbematostss érzékeny bot -sansuwa skm;. rovarcsípés. ólaim? vagy szára?. öőz. faggyütsdpzés* {seborynoiCi roosesanessége*.. íaskatpasPás igibpísts cvsptls}; toaos kopaszoddá (petsdsb esz^eny rssjas poor rsensitivs scsspl .yams Pa·, a najas tájbor p.hkeiysom«&amp; -osomP és p«ra-sórporp (parapsonasis) diszbidroslitkos akcásao {dysh«:ffösís).. szen'ptés és ΐ|ο$§.?οΡ rabi segeiafts ^é«c^$*|es|paf' oPsltts) as Párna. € Az 1, igénypont szadati kompoztck*. «bot a szaresodés rendellenessége* a PvsiPis kőéi viászibáték aasrasoélsr Csodások ikmim lested). féisz-sfasodáso* tnypoAéíafosp, diszfceratezis, Darter* fals Patapap, parskerarézls. bdrpikimtyosádés (tehthyo**), böilrántatDíP (acsly dermatosis.,. prurigo (vsS?katcvtoxfatvajtoass}< PpasforlbS; S. A? 1 igénypont szsnna kompoz χιό, abol a kezm^y ·ν rcolstoryt vagy emiozgatő (vason totor) roPö'eiieoessopk a € aibybfp; fpprés |fi«íáirrpíöal pnsssbfe} során, Sros'sbovtisos bPratmak. ; ΨΜ$$> app j|b Ipoavy tsg? bstegsóg os t#op:.#^É#b;i|sar8Stft|^á|·: é v? 1 cyr-vpory ssgio η o sp rkv tt'.o o s^bp-^xy- >c<ca'j·? kon) s'ce-'f-na^apc! a kovatsazok kozol visaziatékilk sebék, égést «aosk Ppáésdpé(::fi^itiiis {tlAorvrréss). gnboaliála bespsáp. a oor foko?c4f posltrm· ; éápéSé (eutaasoos porgbyrkfl és srdagaoslok toogloma}.
HUE12186394A 2007-02-13 2008-02-08 Új kozmetikai és/vagy gyógyászati kompozíció és ennek alkalmazása HUE032072T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0701011A FR2912310B1 (fr) 2007-02-13 2007-02-13 Nouvelles compositions cosmetiques et/ou pharmaceutiques et leurs applications.

Publications (1)

Publication Number Publication Date
HUE032072T2 true HUE032072T2 (hu) 2017-09-28

Family

ID=38461859

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12186394A HUE032072T2 (hu) 2007-02-13 2008-02-08 Új kozmetikai és/vagy gyógyászati kompozíció és ennek alkalmazása

Country Status (19)

Country Link
US (2) US8361522B2 (hu)
EP (2) EP2606874B1 (hu)
JP (2) JP5868572B2 (hu)
KR (1) KR101361186B1 (hu)
CN (1) CN101631529B (hu)
AR (2) AR065314A1 (hu)
BR (1) BRPI0808065B1 (hu)
CY (2) CY1116220T1 (hu)
DK (2) DK2606874T3 (hu)
ES (2) ES2529696T3 (hu)
FR (1) FR2912310B1 (hu)
HR (2) HRP20150128T1 (hu)
HU (1) HUE032072T2 (hu)
LT (1) LT2606874T (hu)
PL (2) PL2134316T3 (hu)
PT (2) PT2134316E (hu)
SI (2) SI2134316T1 (hu)
TW (1) TWI433680B (hu)
WO (1) WO2008113912A2 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2600822A2 (en) * 2010-08-05 2013-06-12 Legacy Healthcare Holding Ltd. Method for stimulating hair growth
CA2826235A1 (en) * 2011-02-23 2012-08-30 Legacy Healthcare Ltd New use of compositions for preventing chemotherapy and radiotherapy induced alopecia (cria), reducing cria impact and improving the appearance of hair re-growth after cria
WO2012140013A2 (en) 2011-04-11 2012-10-18 Legacy Healthcare Holding Ltd New use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling.
WO2013020719A2 (en) 2011-08-09 2013-02-14 Legacy Healthcare Holding Ltd New use of compositions to delay the onset of the catagen phase of the hair
JP5769611B2 (ja) * 2011-12-08 2015-08-26 株式会社ピカソ美化学研究所 育毛剤組成物
WO2014092684A2 (en) * 2012-12-11 2014-06-19 Avon Products, Inc. Use of melicope extracts to improve conditions caused by excess lipids
EP2862598A1 (en) * 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Use of a composition for the pigmentation of hair and hairs
BR112016009931B1 (pt) 2013-11-08 2021-02-02 Legacy Healthcare Ltd composição para uso para a inibição da progressão de tumor e redução do tamanho de tumor e para o tratamento de comorbidades do câncer
EP2905028A1 (en) * 2014-02-07 2015-08-12 Legacy Healthcare Holding Ltd. Method of neutralizing the odor of onion
WO2017186954A1 (en) 2016-04-28 2017-11-02 Legacy Healthcare Ltd Method for the improvement of speed and endurance capacity
CN108114588A (zh) * 2016-11-29 2018-06-05 金红叶纸业集团有限公司 一种植物型除臭组合物及生活用纸
TWI636794B (zh) 2017-11-06 2018-10-01 吳治增 一種奈米複合材料及其應用
WO2019134760A1 (en) 2018-01-08 2019-07-11 Legacy Healthcare (Switzerland) Sa Method for assessing hair loss and scalp disorders
FR3109881B1 (fr) * 2020-05-07 2022-10-21 Legacy Healthcare Switzerland Sa Procede pour ameliorer le systeme immun pour acquerir la pan-immunite
KR102278055B1 (ko) * 2021-02-15 2021-07-16 주식회사 코씨드바이오팜 과라나 추출물을 유효성분으로 함유하는 비듬 및 두피 가려움증 개선용 화장료 조성물
US20240156734A1 (en) * 2022-11-11 2024-05-16 Michael Farber Simplified Method for Making Shelf Stable Highly Water Soluble Anhydrous Compositions Of Cyclodextrin Complexes of Macrocyclic Lactones
US11819530B1 (en) * 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229342A (en) 1977-05-18 1980-10-21 Rhone-Poulenc Industries Process for extracting proteins from milk using silica and anion exchange resins
DE2844614A1 (de) * 1978-10-13 1980-05-08 Alfred Czypull Bio-aktiv-haartinktur
NL8204923A (nl) 1982-12-21 1984-07-16 Stichting Nl I Zuivelonderzoek Werkwijze voor het bereiden van een precipitaat van caseine en wei-eiwit alsmede aldus bereid precipitaat.
JPS61178910A (ja) * 1985-02-02 1986-08-11 Akio Fujikawa 育毛養毛等美髪料
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
JP2676155B2 (ja) * 1988-08-11 1997-11-12 株式会社資生堂 養毛料
JP2673252B2 (ja) * 1988-08-11 1997-11-05 株式会社資生堂 養毛料
JP2871763B2 (ja) * 1989-12-15 1999-03-17 株式会社資生堂 テストステロン―５α―レダクターゼ阻害剤
JPH03227911A (ja) * 1990-01-31 1991-10-08 Yutaka Miyauchi 育毛剤
JPH04342517A (ja) * 1990-07-20 1992-11-30 Yutaka Miyauchi ５α−リダクターゼ阻害剤
US6984772B1 (en) 1994-02-18 2006-01-10 Virginia Tech Intellectual Properties, Inc. Transgenic non-human mammals producing fibrinogen in their milk
CH682217A5 (en) * 1991-05-23 1993-08-13 Linda Singer Dolla Hair lotion comprising aq. alcoholic extract of natural plant material - and aromatic plant substances and prepn., for treating or preventing baldness
FR2706771A1 (en) * 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
JPH0733673A (ja) * 1993-07-19 1995-02-03 Taisho Pharmaceut Co Ltd テストステロン−５α−リダクターゼ阻害剤
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
DE19533777A1 (de) * 1995-09-12 1997-03-13 Walther Aria Ellen Haarwuchsmittel
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US5773241A (en) * 1996-09-05 1998-06-30 Ericsson; Arthur Dale Preparation of bioactive extracts
JP2000044439A (ja) * 1998-07-31 2000-02-15 Shiseido Co Ltd 頭皮頭髪用組成物
JP2000247830A (ja) * 1999-02-26 2000-09-12 Nagase & Co Ltd エラスターゼ阻害剤
US6183803B1 (en) 1999-06-11 2001-02-06 Biosante Pharmaceuticals, Inc. Method for processing milk
JP2001081037A (ja) * 1999-09-09 2001-03-27 Ichimaru Pharcos Co Ltd 化粧料組成物
DE10035735C2 (de) * 2000-07-22 2003-02-20 Wella Ag Haartonikum zur Vorbeugung oder Behandlung von Haarausfall
EP1228769A1 (de) * 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiontisches Regenerativum
ATE420108T1 (de) 2001-07-20 2009-01-15 Campina Bv Verfahren zur herstellung von preparationen aus milchprodukten, welche wachstumsfaktoren (tgf- beta und igf-1), lactoperoxidase und immunglobuline mit niedriger gegenseitiger verunreinigung enthalten
US20030077336A1 (en) * 2001-10-10 2003-04-24 Maf Group, Llc Anti-inflammatory complex containing flaxseed oil
JP2003201229A (ja) * 2001-10-23 2003-07-18 Shiseido Co Ltd マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料
JP3886117B2 (ja) * 2002-05-16 2007-02-28 株式会社ノエビア 皮膚外用剤
JP3886116B2 (ja) * 2002-05-16 2007-02-28 株式会社ノエビア 皮膚外用剤
JP2004123622A (ja) * 2002-10-03 2004-04-22 Toyo Shinyaku:Kk 血流改善外用剤
DE102004011968A1 (de) * 2004-03-10 2005-09-29 Henkel Kgaa Präbiotisch wirksame Pflanzenextrakte
JP3853773B2 (ja) * 2003-09-19 2006-12-06 花王株式会社 養毛料
JP2005194246A (ja) * 2004-01-09 2005-07-21 Ichimaru Pharcos Co Ltd ＮＦ−κＢ活性化抑制剤
US20060018867A1 (en) * 2004-05-12 2006-01-26 Ichimaru Pharcos Co., Ltd Cosmetic composition and production thereof
JP2008500972A (ja) 2004-05-14 2008-01-17 キリンファーマ株式会社 免疫グロブリンの精製方法
WO2005120452A1 (en) * 2004-06-07 2005-12-22 Katica Pavlovic A procedure in production of a curative creams for regeneration of skin tissue, easer breathing, psoriasis, pains and tiredness in legs
DE202004012348U1 (de) * 2004-08-03 2004-10-07 Jabal Amman, Suhbi Hasan Mohammes Zubereitung zur Pflege der Haut bei Psoriasis oder Ekzem
FR2875403A1 (fr) 2004-09-20 2006-03-24 Fatima Basri Composition favorisant l'angiofenese
JP2006104098A (ja) * 2004-10-04 2006-04-20 Ichimaru Pharcos Co Ltd ヒアルロニダーゼ活性阻害剤
FR2877219B1 (fr) * 2004-10-28 2007-03-09 Fatima Basri Composition utilisee en cosmetique ou en pharmacologie pour stimuler la synthese du collagene
FR2877224B1 (fr) 2004-10-28 2007-03-09 Fatima Basri Utilisation d'une composition pour la fabrication d'un medicament destine au traitement des cancers
FR2877408A1 (fr) 2004-10-29 2006-05-05 Faurecia Bloc Avant Composant pour vehicule automobile comprenant un corps en matiere plastique et une bague de renfort metallique, et vehicule correspondant
FR2877576B1 (fr) * 2004-11-08 2007-03-09 Ahmed Kadri Composition pharmaceutique utilisee pour stimuler la proliferation et l'activation des mastocytes
CA2629529A1 (en) * 2004-11-18 2006-05-26 Biopharmacopae Design International Inc. Plant extracts and dermatological uses thereof
DE102005010142A1 (de) * 2005-03-02 2005-11-03 Dr. Kurt Wolff Gmbh & Co. Kg Mittel zur Aktivierung der Haarwurzeln und Verwendung des Mittels
JP4804805B2 (ja) * 2005-06-10 2011-11-02 横関油脂工業株式会社 細胞賦活剤、紫外線障害緩和剤及びメラニン産生抑制剤

Also Published As

Publication number Publication date
CY1119968T1 (el) 2018-12-12
PL2134316T3 (pl) 2015-06-30
PT2134316E (pt) 2015-02-24
CY1116220T1 (el) 2017-02-08
WO2008113912A2 (fr) 2008-09-25
ES2602986T3 (es) 2017-02-23
HRP20161521T1 (hr) 2016-12-16
US20130108719A1 (en) 2013-05-02
FR2912310A1 (fr) 2008-08-15
PT2606874T (pt) 2016-11-02
EP2606874A3 (fr) 2013-08-14
AR110194A2 (es) 2019-03-06
BRPI0808065B1 (pt) 2018-02-06
AR065314A1 (es) 2009-05-27
JP2010518180A (ja) 2010-05-27
DK2134316T3 (en) 2015-02-16
LT2606874T (lt) 2016-12-12
EP2606874A2 (fr) 2013-06-26
WO2008113912A3 (fr) 2008-12-11
US8361522B2 (en) 2013-01-29
HRP20150128T1 (hr) 2015-04-24
KR101361186B1 (ko) 2014-02-07
US8652543B2 (en) 2014-02-18
CN101631529B (zh) 2013-01-09
FR2912310B1 (fr) 2009-08-07
TWI433680B (zh) 2014-04-11
EP2606874B1 (fr) 2016-08-17
SI2606874T1 (sl) 2016-11-30
BRPI0808065A2 (pt) 2014-08-05
US20100104671A1 (en) 2010-04-29
EP2134316B1 (fr) 2014-11-19
TW200833351A (en) 2008-08-16
JP5868572B2 (ja) 2016-02-24
ES2529696T3 (es) 2015-02-24
EP2134316A2 (fr) 2009-12-23
DK2606874T3 (en) 2016-12-05
KR20090123856A (ko) 2009-12-02
JP2014177498A (ja) 2014-09-25
JP5922715B2 (ja) 2016-05-24
PL2606874T3 (pl) 2017-02-28
SI2134316T1 (sl) 2015-03-31
CN101631529A (zh) 2010-01-20

Similar Documents

Publication Publication Date Title
HUE032072T2 (hu) Új kozmetikai és/vagy gyógyászati kompozíció és ennek alkalmazása
Ying et al. Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated activation of caspase-8-/caspase-3-dependent pathway
Ho et al. Berberine induced apoptosis via promoting the expression of caspase-8,-9 and-3, apoptosis-inducing factor and endonuclease G in SCC-4 human tongue squamous carcinoma cancer cells
Saha et al. Inhibition of calcium oxalate crystallisation in vitro by an extract of Bergenia ciliata
Rashid et al. Mitigation of 5-Fluorouracil induced renal toxicity by chrysin via targeting oxidative stress and apoptosis in wistar rats
Kam et al. Apoptosis: mechanisms and clinical implications
Chen et al. Gypenosides induced apoptosis in human colon cancer cells through the mitochondria-dependent pathways and activation of caspase-3
Wu et al. Physalin F induces cell apoptosis in human renal carcinoma cells by targeting NF-kappaB and generating reactive oxygen species
Lu et al. Gypenosides induced G0/G1 arrest via inhibition of cyclin E and induction of apoptosis via activation of caspases-3 and-9 in human lung cancer A-549 cells
Yang et al. ZnO quantum dots induced oxidative stress and apoptosis in HeLa and HEK-293T cell lines
Sonika et al. Comparative studies on anti-inflammatory activity of Coriandrum sativum, Datura stramonium and Azadirachta indica
Abdullah et al. A natural compound from Hydnophytum formicarium induces apoptosis of MCF-7 cells via up-regulation of Bax
Ichwan et al. Anti-neoplastic potential of ethyl-p-methoxycinnamate of Kaempferia galanga on oral cancer cell lines
JP7421464B2 (ja) 頭皮用剤
Oliaee et al. Evaluation of cytotoxicity and antifertility effect of Artemisia kopetdaghensis
Sezer An in vitro assessment of the cytotoxic and apoptotic potency of silymarin and silymarin loaded solid lipid nanoparticles on lung and breast cancer cells
Ayinde et al. Effects of the aqueous extract of Ficus capensis Thunb.(Moraceae) leaf on gastrointestinal motility
Injac Potential medical use of fullerenols after two decades of oncology research
Chou et al. The synthesized 2-(2-fluorophenyl)-6, 7-methylenedioxyquinolin-4-one (CHM-1) promoted G2/M arrest through inhibition of CDK1 and induced apoptosis through the mitochondrial-dependent pathway in CT-26 murine colorectal adenocarcinoma cells
Mukunda et al. Cytotoxic effect of anise seed (Pimpinella anisum) extract on KB cell line-a comparative study with CISPLATIN.
Sikder et al. Evaluation of pharmacological and toxicological studies of Ayurvedic medicine Siddha Makardhwaja on biological system of male Sprague-Dawley rats
Atmaca et al. Synthesis of silver nanoparticles using Alpinia officinarum rhizome extract induces apoptosis through down-regulating Bcl-2 in human cancer cells
Pérez-Sánchez et al. Rosemary (Rosmarinus officinalis L) extract increases ROS and modulates Nrf2 pathway in human colon cancer cell lines
Dobhal et al. Cardioprotective potential of Allium humile leaves extract
Cherdshewasart et al. Antimutagenic potential of the Thai herb, Mucuna collettii Lace